C-reactive protein guided use of procalcitonin in COVID-19
| Autor: | Rebecca Houghton, Nathan Moore, Rebecca Williams, Maryanna Tavener, Tom Durham, Gabriele Pollara, Jack Bowyer, Kordo Saeed, Fatima El-Bakri, Jonathan E. Peters, Matilde Mori, Gabrielle Vernet, Jessica Lynch, Henry Lewis |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
congenital
hereditary and neonatal diseases and abnormalities medicine.medical_specialty biology Coronavirus disease 2019 (COVID-19) business.industry C-reactive protein bacterial infections and mycoses Predictive value Gastroenterology Procalcitonin Increased risk Standard care Internal medicine parasitic diseases Hospital admission Cohort biology.protein Medicine business hormones hormone substitutes and hormone antagonists |
| DOI: | 10.1101/2021.02.10.21251350 |
| Popis: | Background A low procalcitonin (PCT) concentration facilitates exclusion of bacterial co-infections in COVID-19, but high costs associated with PCT measurements preclude universal adoption. Changes in inflammatory markers, including C-reactive protein (CRP), can be concordant, and predicting low PCT concentrations may avoid costs of redundant tests and support more cost-effective deployment of this diagnostic biomarker. Objectives To explore whether, in COVID-19, low PCT values could be predicted by the presence of low CRP concentrations. Methods Unselected cohort of 224 COVID-19 patients admitted to hospital that underwent daily PCT and CRP measurements as standard care. Both 0.25 ng/mL and 0.5 ng/mL were used as cut-offs for positive PCT test results. Geometric mean was used to define high and low CRP values at each timepoint assessed. Results Admission PCT was 0.5 ng/mL in 37 (16.5%). Elevated PCT was associated with increased risk of death (P = 0.0004) and was more commonly associated with microbiological evidence of bacterial co-infection (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|